GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oramed Pharmaceuticals Inc (XTAE:ORMP) » Definitions » Cyclically Adjusted PB Ratio

Oramed Pharmaceuticals (XTAE:ORMP) Cyclically Adjusted PB Ratio : 0.73 (As of May. 29, 2025)


View and export this data going back to 2017. Start your Free Trial

What is Oramed Pharmaceuticals Cyclically Adjusted PB Ratio?

As of today (2025-05-29), Oramed Pharmaceuticals's current share price is ₪7.688. Oramed Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 was ₪10.53. Oramed Pharmaceuticals's Cyclically Adjusted PB Ratio for today is 0.73.

The historical rank and industry rank for Oramed Pharmaceuticals's Cyclically Adjusted PB Ratio or its related term are showing as below:

XTAE:ORMP' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.7   Med: 3.17   Max: 16.95
Current: 0.79

During the past years, Oramed Pharmaceuticals's highest Cyclically Adjusted PB Ratio was 16.95. The lowest was 0.70. And the median was 3.17.

XTAE:ORMP's Cyclically Adjusted PB Ratio is ranked better than
63.43% of 670 companies
in the Biotechnology industry
Industry Median: 1.485 vs XTAE:ORMP: 0.79

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Oramed Pharmaceuticals's adjusted book value per share data for the three months ended in Mar. 2025 was ₪12.076. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is ₪10.53 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


Oramed Pharmaceuticals Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Oramed Pharmaceuticals's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oramed Pharmaceuticals Cyclically Adjusted PB Ratio Chart

Oramed Pharmaceuticals Annual Data
Trend Aug15 Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Dec22 Dec23 Dec24
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.39 11.67 5.32 0.88 0.86

Oramed Pharmaceuticals Quarterly Data
May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.09 0.94 0.88 0.86 0.75

Competitive Comparison of Oramed Pharmaceuticals's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Oramed Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oramed Pharmaceuticals's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oramed Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Oramed Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.


;
;

Oramed Pharmaceuticals Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Oramed Pharmaceuticals's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=7.688/10.53
=0.73

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oramed Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Oramed Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Mar. 2025 was:

Adj_Book=Book Value per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=12.076/134.9266*134.9266
=12.076

Current CPI (Mar. 2025) = 134.9266.

Oramed Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201505 6.894 100.333 9.271
201508 7.522 100.548 10.094
201511 6.806 100.135 9.171
201602 8.740 100.040 11.788
201605 8.266 101.355 11.004
201608 6.960 101.617 9.241
201611 6.333 101.829 8.391
201702 5.620 102.779 7.378
201705 5.211 103.256 6.809
201708 4.931 103.587 6.423
201711 5.568 104.072 7.219
201802 4.980 105.052 6.396
201805 4.033 106.148 5.126
201808 6.275 106.383 7.959
201811 5.818 106.338 7.382
201902 5.109 106.649 6.464
201905 4.345 108.048 5.426
201908 3.908 108.245 4.871
201911 3.455 108.519 4.296
202002 2.441 109.139 3.018
202005 5.134 108.175 6.404
202008 4.865 109.662 5.986
202011 4.151 109.793 5.101
202102 6.123 110.968 7.445
202105 7.818 113.576 9.288
202108 11.492 115.421 13.434
202111 15.652 117.269 18.009
202203 14.748 121.301 16.405
202206 13.963 125.017 15.070
202209 13.776 125.227 14.843
202212 13.443 125.222 14.485
202303 13.232 127.348 14.019
202306 13.201 128.729 13.837
202309 12.970 129.860 13.476
202312 14.227 129.419 14.832
202403 14.408 131.776 14.752
202406 15.268 132.554 15.541
202409 13.630 133.029 13.824
202412 12.836 133.157 13.007
202503 12.076 134.927 12.076

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Oramed Pharmaceuticals  (XTAE:ORMP) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Oramed Pharmaceuticals Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Oramed Pharmaceuticals's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Oramed Pharmaceuticals Business Description

Traded in Other Exchanges
Address
1185 Avenue of the Americas, Third Floor, New York, NY, USA, 10036
Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. developed an oral dosage form intended to withstand the harsh environment of the stomach and effectively deliver active biological insulin or other proteins. Its product pipeline includes ORMD-0801, ORMD-0801, and ORMD 0901.